The next generation of antiemetics for the management of postoperative nausea and vomiting
| Autor: | Geertrui Dewinter, Hon Sen Tan, Ashraf S. Habib |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Rolapitant Efficacy 03 medical and health sciences 0302 clinical medicine Neurokinin-1 Receptor Antagonists 030202 anesthesiology Humans Serotonin 5-HT3 Receptor Antagonists Medicine Amisulpride Intensive care medicine Adverse effect Aprepitant Randomized Controlled Trials as Topic business.industry Palonosetron Disease Management Anesthesiology and Pain Medicine Postoperative Nausea and Vomiting Antiemetics Dopamine Antagonists Drug Therapy Combination medicine.symptom business 030217 neurology & neurosurgery Postoperative nausea and vomiting medicine.drug |
| Zdroj: | Best Practice & Research Clinical Anaesthesiology. 34:759-769 |
| ISSN: | 1521-6896 |
| DOI: | 10.1016/j.bpa.2020.11.004 |
| Popis: | Postoperative nausea and vomiting (PONV) afflict approximately 30% of patients overall and up to 80% of high-risk patients after surgery. Optimal pharmacological prophylaxis of PONV is challenging as it necessitates the consideration of PONV risk, drug efficacy, and potential adverse effects. Despite significant advances in our understanding of the pathophysiology and risk factors of PONV, its incidence has remained largely unchanged. Newer antiemetics have been introduced that may have improved safety profiles, longer duration of action, and better efficacy. This review aims to summarize the recent developments pertaining to these new agents and their potential application toward the management of PONV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|